UNSPSC 51162021: Formoterol/mometasone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162021 Formoterol/mometasone is a Commodity code that does not align with the state and local contract opportunities currently posted under it. The recent solicitations tagged with this code focus on naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which involve formoterol/mometasone or other branded inhalation therapies for respiratory conditions. The mismatch suggests either a data-entry error in the UNSPSC tagging applied by issuing bodies or a disconnect between the code's nominal scope and how state and local procurement offices are currently deploying it in practice.

The issuing bodies soliciting under the current tag include county health departments (Seminole County, Florida), county government employer health plans (Hall County, Georgia), a state health and human services commission (Texas HHS Commission), and a multi-state cooperative purchasing alliance (MMCAP, administered by Minnesota). Recent representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), Hall County's RFQ for on-site pharmacy services (due June 4, 2026), Texas HHS Commission's RFI for direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). Given this material gap between the code's stated product and the work being actually solicited, the code shows little relevant recent activity for vendors focused on formoterol/mometasone or similar branded respiratory inhalation therapies.